Abstract
Objective: To evaluate a simultaneous PET/MRI approach to imaging patients with neuroendocrine tumor using a combination of 68Ga-DOTA-TOC as a PET contrast agent and gadoxetate disodium as a hepatobiliary MRI contrast agent. Materials and methods: Ten patients with neuroendocrine tumor with known or suspected hepatic disease were imaged using a 68Ga-DOTA-TOC PET/CT immediately followed by a 3.0T time-of-flight PET/MRI, using a combined whole body and liver specific imaging. The presence of lesions and DOTA-TOC avidity were assessed on CT, PET from PET/CT, diffusion weighted imaging, hepatobiliary phase imaging (HBP), and PET from PET/MRI. Maximum standardized uptake values (SUVmax) in hepatic lesions and nodal metastases were compared between PET/CT and PET/MRI, as were detection rates using each imaging approach. Results: A total of 101 hepatic lesions were identified, 47 of which were DOTA-TOC avid and able to be individually measured on both PET/CT and PET/MRI. HBP imaging had a higher sensitivity for detection of hepatic lesions compared to CT or PET (99% vs. 46% and 64%, respectively; p values <0.001). There was a strong correlation between SUVmax of liver lesions obtained with PET/CT compared to PET/MR imaging (Pearson’s correlation = 0.91). For nodal disease, CT had a higher sensitivity compared to whole body MRI (p = 0.015), although PET acquired from PET/MRI detected slightly more lesions compared to PET from PET/CT. Conclusions: A simultaneous PET/MRI using both 68Ga-DOTA-TOC and gadoxetate disodium was successful in whole body staging of patients with neuroendocrine tumor. HBP imaging had an increased detection rate for hepatic metastases.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1432-1440 |
| Number of pages | 9 |
| Journal | Abdominal Imaging |
| Volume | 40 |
| Issue number | 6 |
| DOIs | |
| State | Published - Aug 12 2015 |
| Externally published | Yes |
Fingerprint
Keywords
- Ga-68 DOTA-TOC
- Hepatobiliary agents
- Neuroendocrine tumor
- PET/MRI
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
- Radiology Nuclear Medicine and imaging
- Gastroenterology
- Urology
Cite this
Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. / Hope, Thomas A.; Pampaloni, Miguel Hernandez; Nakakura, Eric; VanBrocklin, Henry; Slater, James; Jivan, Salma; Aparici, Carina Mari; Yee, Judy; Bergsland, Emily.
In: Abdominal Imaging, Vol. 40, No. 6, 12.08.2015, p. 1432-1440.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor
AU - Hope, Thomas A.
AU - Pampaloni, Miguel Hernandez
AU - Nakakura, Eric
AU - VanBrocklin, Henry
AU - Slater, James
AU - Jivan, Salma
AU - Aparici, Carina Mari
AU - Yee, Judy
AU - Bergsland, Emily
PY - 2015/8/12
Y1 - 2015/8/12
N2 - Objective: To evaluate a simultaneous PET/MRI approach to imaging patients with neuroendocrine tumor using a combination of 68Ga-DOTA-TOC as a PET contrast agent and gadoxetate disodium as a hepatobiliary MRI contrast agent. Materials and methods: Ten patients with neuroendocrine tumor with known or suspected hepatic disease were imaged using a 68Ga-DOTA-TOC PET/CT immediately followed by a 3.0T time-of-flight PET/MRI, using a combined whole body and liver specific imaging. The presence of lesions and DOTA-TOC avidity were assessed on CT, PET from PET/CT, diffusion weighted imaging, hepatobiliary phase imaging (HBP), and PET from PET/MRI. Maximum standardized uptake values (SUVmax) in hepatic lesions and nodal metastases were compared between PET/CT and PET/MRI, as were detection rates using each imaging approach. Results: A total of 101 hepatic lesions were identified, 47 of which were DOTA-TOC avid and able to be individually measured on both PET/CT and PET/MRI. HBP imaging had a higher sensitivity for detection of hepatic lesions compared to CT or PET (99% vs. 46% and 64%, respectively; p values <0.001). There was a strong correlation between SUVmax of liver lesions obtained with PET/CT compared to PET/MR imaging (Pearson’s correlation = 0.91). For nodal disease, CT had a higher sensitivity compared to whole body MRI (p = 0.015), although PET acquired from PET/MRI detected slightly more lesions compared to PET from PET/CT. Conclusions: A simultaneous PET/MRI using both 68Ga-DOTA-TOC and gadoxetate disodium was successful in whole body staging of patients with neuroendocrine tumor. HBP imaging had an increased detection rate for hepatic metastases.
AB - Objective: To evaluate a simultaneous PET/MRI approach to imaging patients with neuroendocrine tumor using a combination of 68Ga-DOTA-TOC as a PET contrast agent and gadoxetate disodium as a hepatobiliary MRI contrast agent. Materials and methods: Ten patients with neuroendocrine tumor with known or suspected hepatic disease were imaged using a 68Ga-DOTA-TOC PET/CT immediately followed by a 3.0T time-of-flight PET/MRI, using a combined whole body and liver specific imaging. The presence of lesions and DOTA-TOC avidity were assessed on CT, PET from PET/CT, diffusion weighted imaging, hepatobiliary phase imaging (HBP), and PET from PET/MRI. Maximum standardized uptake values (SUVmax) in hepatic lesions and nodal metastases were compared between PET/CT and PET/MRI, as were detection rates using each imaging approach. Results: A total of 101 hepatic lesions were identified, 47 of which were DOTA-TOC avid and able to be individually measured on both PET/CT and PET/MRI. HBP imaging had a higher sensitivity for detection of hepatic lesions compared to CT or PET (99% vs. 46% and 64%, respectively; p values <0.001). There was a strong correlation between SUVmax of liver lesions obtained with PET/CT compared to PET/MR imaging (Pearson’s correlation = 0.91). For nodal disease, CT had a higher sensitivity compared to whole body MRI (p = 0.015), although PET acquired from PET/MRI detected slightly more lesions compared to PET from PET/CT. Conclusions: A simultaneous PET/MRI using both 68Ga-DOTA-TOC and gadoxetate disodium was successful in whole body staging of patients with neuroendocrine tumor. HBP imaging had an increased detection rate for hepatic metastases.
KW - Ga-68 DOTA-TOC
KW - Hepatobiliary agents
KW - Neuroendocrine tumor
KW - PET/MRI
UR - http://www.scopus.com/inward/record.url?scp=84938985126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938985126&partnerID=8YFLogxK
U2 - 10.1007/s00261-015-0409-9
DO - 10.1007/s00261-015-0409-9
M3 - Article
C2 - 25820755
AN - SCOPUS:84938985126
VL - 40
SP - 1432
EP - 1440
JO - Abdominal Radiology
JF - Abdominal Radiology
SN - 2366-004X
IS - 6
ER -